^
Association details:
Biomarker:NF2 mutation
Cancer:Breast Cancer
Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer

Excerpt:
Patients with mesenchymal/MpBC treated with temsirolimus-based regimens were evaluated...Of the eight patients who achieved SD ≥6 months/CR/PR, all 4 patients with available tissue had a molecular aberration that activate the PIK3CA/Akt/mTOR axis: PIK3CA mutation = 2; PTEN loss = 1; NF2 aberration = 1.
Secondary therapy:
temsirolimus + pegylated liposomal doxorubicin
DOI:
10.1093/annonc/mdv163